# **Congestive Heart Failure Tutorial**

One of the costliest illnesses from both a financial point of view and a quality of life point of view is Congestive Heart Failure. Many organizations, including CMS, have initiated targeted CHF Treatment programs to address both. The reality is that a growing number of people are developing CHF at a younger age. And, aggressively treated, it is possible to decrease the morbidity, delay the mortality and decrease the cost of care for this illness.

This is why SETMA developed a CHF Clinic in which to aggressively treat patients with this illness through standardization of therapy and frequent monitoring of the patient's progress.

This disease management tool is built to the standards established by the Physician Consortium for Performance Improvement.

### How to find the CHF Templates

#### AAA Home

Patient [	Home Phone	Test Jr (409)888-888 ent's Code Sta	8 VVork Phor tus DNR	Age 39 DOB 03/25/197 PE () -	
<u>SETMA's LESS In</u> <u>Ch</u>		venting Diabet	<u>es I Preventii</u> ode Tutorial <u>E&amp;I</u>	ng Hypertension I M M Coding Recommendations	edical Home Coordination Needs Attention!! Rheumatology
	dmission Orders	<u>T Discharge</u> <u>T Diabetic E</u>	<u>I Insulin Infusi</u> xercise I Drug		anagement <u>T</u>
Acute Coronary Syn I Angina Patient's Pharmacy		<u>I</u> <u>Diabete</u> Management	se Management <u>s I Headaches</u> <u>I Renal Failure</u>		ardiometabolic Risk Syndrome I
Daleo Pharmacy	Status	Priority	Referral	Referring Provider	Chart Note
	Jaids	rnoncy	Nerenai	nerening Hovider	Return Info
					Return Doc
, and jet i					Email
Rx Sheet - Active					Telephone
Rx Sheet - New					Records Request
Rx Sheet - Complete	•			F	Transfer of Care Doc
Home Health	Archived Pof	errale . Do o	ot use for new r	eferrals Referral History	
	Status	Priority	Referral	Referring Provider	
<b>[</b>					Þ

### Master Tool Bar Icon

DOB 03/25/1970	-	<b>D</b> X
) -		
		New Dock
Show		New       Lock         \$ 11/30/2009 12         \$ 11/30/2009 12         \$ 11/30/2009 12         \$ 11/30/2009 12         \$ 11/30/2009 10         AAA Home         Master Gp         IMAssessmei         IMAssessmei         11/23/2009 02         AAA Home         Diabetes Prev         \$ 11/23/2009 02         11/23/2009 01         11/23/2009 01         10/20/2009 10         10/20/2009 10         10/20/2009 11
Certegories Categories		My Practice
Records Request Transfer of Care Doc		
Referral History		* 2 🏂
•	┛	<b>E</b>

SETMA's CHF Suite of Templates contains the following templates:

- 1. Master CHF
- 2. Nursing
- 3. Histories
- 4. Health
- 5. Questionnaires
- 6. System Review
- 7. Physical Exam
- 8. Radiology
- 9. Procedures

- 10. Treatment Guide
- 11. Treatment Plan
- 12. CHF Questionnaire
- 13. Flowsheet

U	HF Mana	gemer	ıt	Patient Robe	ert Test Jr		Home
Goals of Therapy	Differentia	ting	Causes	Sex	M Age 3	9	Nursing
Diag	nosing	Classificati	on				Histories
/ital Signs			Most Recent	Labs Check for Ne	w Labs		Health
Height	72.00 inches		Sodium	11	Cholesterol 150		Questionnaires
Veight	.00 pound:	s	Potassium	11	Triglycerides 175		System Review
<u>9MI</u>	22 %		Chloride	11	HDL		Physical Exam
<u>Body Fat</u>	<u> </u>		CO2	- 11			
<u>BMR</u> Vaist	cal/day		Glucose		Chol/HDL	_	Radiology
nvaist Hips	00 inches		BUN Creatinine		Trig/HDL UA Protein		Procedures
nips Risk Ratio	.00		Calcium		T3		Treatment Guide
Blood Pressure			Troponin	11	T4	11	Treatment Plan
	/ mmHg		СРК	11	77	11	CHF Questionnaire
Pulse		-	Digoxin	11	T-Uptake	11	
Last Echo	11		PT	11	тѕн	11	Flowsheet
Ejection Fraction		Help	INR	11	proBNP		
/entricular Dys	Systolic	Help	Fibrinogen	11	Sed Rate	11	
CHF Class	Class II	Help	PAI-1	11	D-Dimer	11	
ramingham 10-Y	r Risk	%			1	-	Patient Info
lortality Risk		_		Medical History	Labs Over Tim	e	Provider Info
Hobal Cardio Risl	1.4						CHF Primer
							Treatment
							Diagnosing Adults

Templates 2-9 are exact copies of the templates in the Master GP suite of templates. For explanations of these templates, please refer to the tutorial on the <u>Master GP</u>

#### The CHF tutorial will focus on:

- Master CHF template
- Treatment Guide template
- Treatment Plan template
- CHF Questionnaire template
- Flowsheet template

# Master CHF Template

This template has a top portion and three columns below the materials which are presented at the top of the template.

#### Тор

- Title of the template
- Patient's name, gender and age
- Five buttons:
  - 1. Goals of Therapy
  - 2. Differentiating
  - 3. Causes
  - 4. Diagnosing
  - 5. Classification

CHF Man	agement	Patient Robert	Test Jr		Home	Ē
Goals of Therapy Differen		Sex M	Age 39		Nursing	
Diagnosing	Classification				Histories	
Vital Signs	Most Recent Labs	Check for New Labs			Health	
Height 72.00 inch	es Sodium 🧾	11 Chole:		06/06/2007	Questionnaires	
Weight .00 pour			cerides 175	06/06/2007	System Review	
BMI Body Fat 22 %	Chloride	11 HDL			Physical Exam	
BMR cal/c		11 Chol/H	IDL		Radiology	
Waist .00 inch		// Trig/H			Procedures	
Hips .00 inch	es Creatinine 🦲	11 UA Pr	otein	11		
Risk Ratio	Calcium	// тз		11	Treatment Guide	-
Blood Pressure	Troponin	// T4		11	Treatment Plan	
Pulse		// T7 // T-Upta	aka 📃		CHF Questionnaire	
Last Echo //	Digoxin PT	// TSH			Flowsheet	
Ejection Fraction	Help INR	// proBN	IP	11		
Ventricular Dys Systolic	Help Fibrinogen	// Sed R	ate	11		
CHF Class Class II	Help PAI-1	D-Dim	er 📃	11		
Framingham 10-Yr Risk	%				Patient Info	
Mortality Risk	_	Medical History	abs Over Time		Provider Info	
Giobal Cardio Risk					CHF Primer	
					Treatment	
					Diagnosing Adults	
Global Cardio Risk 1.4						

This pop-up gives the patient a sense of what the successful treatment of CHF should be. This material is printed on the CHF Follow-up note which is given to the patient. The pop-up states:

CHF N	Vanagement 🔋 🦻	atient Robert Test Jr	Home
	Differentiating Causes	Sex M Age 39	Nursing
Diagnosing	Classification		Histories
Vital Signs	Most Recent Labs Ch	heck for New Labs	Health
Height 72.00			Questionnaires
vveigni <u>1.0</u>	m Chf Goals	× 07	System Review
BMI Body Fat 2	Goals of 1	Cherapy -	Physical Exam
BMR			Radiology
vVaist .0	* Improve Symptoms	Control	- Procedures
Hips .0	* Improve Functional Capacity	* Systolic BP < 120 mmHg	
Risk Ratio	* Improve Quality of Life	* Heart Rate	Treatment Guide
Blood Pressure	* Slow or decrease progression	* Weight	Treatment Plan
Pulse	<ul> <li>Slow or decrease progression</li> </ul>		CHF Questionnaire
Last Echo	* Decrease need for Hospitalization	* Fluid Volume	Flowsheet
Ejection Fraction	* Prolong Survival		
Ventricular Dys			_
CHF Class CI Framingham 10-Yr Ri:	ОК	Cancel	
Mortality Risk			Patient Info
Global Cardio Risk	1.4		CHF Primer
			Treatment
			Diagnosing Adults

#### **Goals of Therapy**

#### Clues for Differentiating between Systolic and Diastolic Dysfunction in patients with Heart Failure

One of the most important elements of the treatment of CHF is to determine whether the patient has Diastolic, Systolic or Combined Diastolic/Systolic failure, as the treatment of each differ significantly.

This pop-up lists 18 history, physical exam and procedure results from 5 categories, which are common in the evaluation and treatment of a patient with CHF. When the appropriate check boxes are marked and the "Calculate" button is depressed, a conclusion will appear which suggests the probability of the patient having systolic or diastolic CHF.

Note: It is a useful exercise to click one element at a time and then depressed "Calculate." This will allow you to see the probable impact each of the 18 elements have on the differentiation between systolic and diastolic dysfunction.

When you depress the button entitled **Differentiating**, the following directions and conclusion will be displayed:

# "Select the following clues that are present in the evaluation of this patient. Click the 'Calculate' button at the bottom to view the conclusion."

**Conclusion** -- this will state "The presentation of symptoms is most suggestive of (Diastolic or Systolic) heart failure."

ight Dm Chf Disting			
eight ( dy Fat R ist ist ist ist ist ist ist ist	Clues for Differentiating Betw Dysfunction in Patient Select the following clues that are pres Click the "Calculate" button at the I History History Hypertension Coronary Artery Disease Diabetes Mellitus Valvular Heart Disease Physical Exam Third Heart Sound (S3) Gallop Fourth Heart Sound (S4) Gallop Rales Jugular Venous Distention Edema Displaced Point of Maximal Impulse Mitral Regurgitation	s with Heart Failure	

#### **Causes of CHF**

This is a good review of the differential diagnoses for the causes of CHF. Check Boxes are present to allow you to document any of the conditions which might affect this patient. Any elements of this pop-up which are captured elsewhere in the EMR are automatically populated here.

#### Diagnosing Heart Failure (Boston Criteria for Diagnosing Heart Failure)

This tool is based on the evaluation of three categories: History, Physical, and Chest Radiograph. Once the relevant elements are documented, depressing the "**Calculate**" button will display a result.

Each element has different values based on the weighted score developed by the Boston Criteria. For instance, "resting dyspnea," results in a score of 4, while "dyspnea climbing stairs," only rates a score of 1. The following is the scoring and the conclusions based on the numerical score:

1-3CHF Unlikely4-7CHF Possible8 and higher CHF Definite

The instructions on the pop-up state, "Select the following criteria for this patient and click "Calculate" to review the conclusion."

CHF Man	agement	Patient Robert	Test Jr	Home
Goals of Therapy Differen	tiating Causes	Sex M	Age 39	Nursing
Diagnosing	Classification			Histories
Vital Signs Dm C	hf Diagdhf			<u>×</u>
Height72.00V/eight.00BMI	Category I - History Rest Dyspnea Orthopnea Paroxysmal Noct	(Boston Criteria for D ng criteria for this patient turnal Dyspnea walking on level area simbing am prmality bpm Elevation cm H20 ly asilar nd	Heart Failure viagnosing Heart Failure) t and click calculate to re	eview the conclusion.
4	Alveolar Pulmona Interstitial Pulmon Bilateral Pleural B	ary Edema hary Edema Effusion atio greater than 0.50	ОК	Cancel

#### Classification

This pop-up is instructional and addresses the various pathophysiological classifications of CHF. The pop-up allows you to check the box beside the type of CHF the patient has and this material will then print on the **CHF Follow-up note** and **CHF Chart Document**.

#### **Classification of Heart Failure**

Heart failure is defined as a pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to pump blood at a rate commensurate with metabolic requirements or to do so only from an elevated filling pressure.

CHF Managemen	t	Patient Robert	Test Jr		Home
Goals of Therapy Differentiating	Causes	Sex	M Age 39		Nursing
Diagnosing	n				Histories
Vital Signs	Most Recent Labs	Check for New	Labs		Health
Height 72.00 inches	Sodium	11	Cholesterol 150	¢6/06/2007	Questionnaires
Weight .00 pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review
BMI Body Fat 22 %	Chloride	11	HDL	11	Physical Exam
BMR cal/day	Glucose	11	Chol/HDL		Radiology
Waist .00 inches	BUN	11	Trig/HDL		Procedures
Hips .00 inches	Creatinine	11	UA Protein	11	
Risk Ratio	Calcium	11	тз	11	Treatment Guide
Blood Pressure / mmHq	Troponin	11	T4		Treatment Plan
Pulse	CPK	11	T7 T-Uptake		CHF Questionnaire
Last Echo //	Digoxin	11	TSH	11	Flowsheet
Ejection Fraction Help		11	proBNP	11	
Ventricular Dys Systolic Help	Fibrinogen	11	Sed Rate	11	
CHF Class Class Help	PAI-1	11	D-Dimer	11	
Framingham 10-Yr Risk %				ſ	Patient Info
Mortality Risk Global Cardio Risk 1.4		Medical History	Labs Over Time	J	Provider Info
Global Cardio Risk 1.4					CHF Primer
					Treatment
					Diagnosing Adults
					-

Definitions and descriptions are given for the following classes of CHF:

Chf Class	
	Classification of Heart Failure
	physiological state in which an abnormality of cardiac function is responsible for failure of the heart rate with metabolic requirements or to do so only from an elevated filling pressure.
Type Cl	haracteristics
Diastolic Dysfunction	Normal myocardial contractility, left ventricular volume, and ejection fraction; impaired myocardial relaxation; diminished early diastolic filling. The heart is stiff and does not relax normally after contracting. Even though it may be able to pump a normal amount of blood out of the ventricles, the stiff heart does not allow as much blood to enter its chambers from the veins. As in systolic dysfunction, the blood returning to the heart then accumulates in the veins.
Systolic Dysfunction	Absolute or relative impairment of myocardial contractility, low ejection fraction. In systolic dysfunction, the heart contracts less forcefully and cannot pump out as much of the blood that is returned to it as it normally does. As a result, more blood remains in the lower chambers of the heart (ventricles). Blood then accumulates in the veins.
📕 High Output Heart Failure	Bounding pulses, wide pulse pressure, accentuated heart sounds, peripheral vasodilatation, increas cardiac output and ejection fraction, moderate four-chamber enlargement.
Low Cardiac Output Syndrome	Fatigue, loss of lean body mass, prerenal azotemia, peripheral vasoconstriction, reduced left or right contractility.
☐ Right Heart Failure	Dependent edema, jugular venous distention, right atrial and ventricular dilatation, reduced right-sided contractility. This occurs when the left ventricle functions poorly. Water may build up within the lungs causing shortness of breath or coughing. The shortness of breath can occur during physical exertion (eg, climbing a flight of stairs), while straining (eg, lifting a heavy object), or can happen when lying dowr An individual may be awakened from sleep by this shortness of breath and start coughing. Feeling tired or weak can also occur.
🗖 Left Heart Failure	Dyspnea, pulmonary vascular congestion, reduced left-sided contractility. This occurs when the right ventricle functions poorly. The volume of blood returning to the heart is decreased, causing swelling (edema) of the body. This fluid build-up is usually first noted in the ankle but can progress up the legs and into other parts of the body. Weight gain can also occur because o the extra water retained within the body.
Eiventricular Heart Failure Biventricular Heart Failure	Dyspnea, dependent edema, jugular venous distention, pulmonary vascular congestion, bilateral reduced contractility. CHF is usually a combination of both RIGHT-SIDED and LEFT-SIDED Heart Failure.

Beneath these five buttons are three columns on the Master CHF Template

#### Column 1

Vital Signs

Height Weight BMI Body Fat BMR Waist Hips **Risk Ratio Blood Pressure** Pulse Last Echo -- this will interact with the Heath Maintenance template to note the date of the last echo. Ejection Fraction -- the percent value for the ejection fraction should be manually entered here. Ventricular Dysfunction -- the evaluation of whether the patient has diastolic or systolic

dysfunction, both or neither, needs to be documented here. When this is documented here, it interacts with the Treatment Guide template.

CHF Class -- the description of the classes of CHF are attached to this name. When this is documented here, it interacts with the Treatment Guide template.

Framingham 10-Yr Risk -- this documents the Framingham Risk Score. For information on how to use the Framingham template see the Framingham tutorial.

Mortality Risk -- this is a new algorithm which assesses the risk of short term death from CHF. This was developed for in-patient use and has limited benefit in the outpatient setting.

Global Cardio Risk -- for information on this score and its significance see the Framingham tutorial.

CHF Managemen	t	Patient Robert	Test Jr		Home	<b>^</b>
Goals of Therapy Differentiating	Causes	Sex	M Age 39		Nursing	
Diagnosing Classificatio	0				Histories	
Vital Signs	Most Recent Labs	Check for New	Labs		Health	
Height 72.00 inches	Sodium	11	Cholesterol 150	06/06/2007	Questionnaires	
vVeight00 pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review	
Body Fat 22 %	Chloride	11	HDL		Physical Exam	
BMR cal/day	Glucose	11	Chol/HDL		Radiology	
vVaist 00 inches	BUN	11	Trig/HDL		Procedures	
Hips .00 inches	Creatinine	11	UA Protein		Treatment Guide	
Risk Ratio Blood Pressure	Calcium	11	T3	11	Treatment Plan	
/ mmHg	СРК	11	17	11	CHF Questionnaire	
Pulse	Digoxin	11	T-Uptake	11	Flowsheet	
Last Echo / / Ejection Fraction Help	PT	11	TSH proBNP		Flowsheet	
Ventricular Dys Systolic Help	Fibrinogen	11	Sed Rate	11		
CHF Class Class II Help	PAI-1	11	D-Dimer	11		
Framingham 10-Yr Risk%				1	Patient Info	
Mortality Risk Global Cardio Risk 1.4		Medical History	Labs Over Time	J	Provider Info	
Giobal Cardio Nisk					CHF Primer	
	•				Treatment Diagnosing Adults	
					Diagnooling Addito	
						_
						•

#### Column 2

Check for New Labs

Most Recent Labs

Medical History -- this launches a pop-up on which 14 different issues related to cardiac history are documented. Where this information is captured in the EMR, it is auto posted here. Where it is not, it will need to be manually added.

Labs Over time

Patient Robert	: Test Jr		Home
s Sex	M Age 39		Nursing
			Histories
Recent Labs Check for New	/Labs		Health
	Cholesterol 150	06/06/2007	Questionnaires
		06/06/2007	System Review
			Physical Exam
		111	
			Radiology
	UA Protein	11	Procedures
n //	тз	11	Treatment Guide
in 11	T4	11	Treatment Plan
11	17		CHF Questionnaire
			Flowsheet
			- Howsheet
11		11	
			Patient Info
Medical History	Labs Over Time		Provider Info
			CHF Primer
			Treatment
			Diagnosing Adults
	n ///	n     ///     Cholesterol     150       sium     ///     Triglycerides     175       le     ///     HDL     I       ///     LDL     I       se     ///     Chol/HDL       ///     Trig/MDL       inin     ///     TA       inin     ///     T4       inin     ///     T6       inin     ///     T6       inin     ///     T6       inin     ///     D0       inin     ///     D0	n       //       Cholesterol       150       06/06/2007         sium       //       Triglycerides       175       06/06/2007         ide       //       HDL       //         ide       //       HDL       //         ide       //       LDL       //         ide       //       Chol/HDL       //         se       //       Chol/HDL       //         inine       //       UA Protein       ///         inin       //       T3       //         inin       //       T4       //         inin       //       T5H       //         inin       //       I       inin         inin       //       I       inin         inin       //       I       Inin

X

#### Dm Chf Medhx **Medical History** ● No C Yes History of myocardial infarction? ⊙ No ○ Yes Hypertension No C Yes Valvular Heart Disease ⊙ No ○ Yes Diabetes ● No ○ Yes Peripheral Vascular Disease No C Yes Hypercholestrolemia No C Yes Rheumatic Fever ● No ○ Yes Chest Irradiation ● No C Yes Exposure to Antineoplastic Agents (e.g. Anthracycline, Trastuzunab) O No 💿 Yes - Alcohol Use 🖲 No 🔘 Yes 🛛 Illicit Drug Use ● No ● Yes Exposure to Sexually Transmitted Disease ● No ○ Yes Family History of Atherosclerotic disease or cardiomyopathy, sudden death, conduction system disease and cardiomyopathy OK Cancel

# Column 3

#### Navigation Buttons

Patient Robert Test Jr	Home
Causes Sex M Age 39	Nursing
	Histories
Most Recent Labs Check for New Labs	Health
Sodium / / Cholesterol 150 06/06/2007	Questionnaires
Potassium // Triglycerides 175 06/06/2007	System Review
Chloride HDL //	
	Physical Exam
Glucose Chol/HDL	Radiology
BUN Trig/HDL	Procedures
Creatinine UA Protein UA Protein	
	Treatment Guide
	Treatment Plan
СРК // 17 // СН	CHF Questionnaire
Digoxin // T-Uptake ///	
PT TSH //	Flowsheet
INR // proBNP //	
Fibrinogen // Sed Rate //	
PAI-1 D-Dimer 11	
	Patient Info
Medical History Labs Over Time	Provider Info
	CHF Primer
	Treatment
Di	Diagnosing Adults
	nagricoling Hadato

The final five buttons within the navigation scheme are all document related.

**Patient Info** – This button will launch a pop-up window that will allow the user to choose from a list of 15 patient-related documents.

C	HF Manageme	nt Patient Robert 1	'est Jr Home
Goals of Therapy	-		ge 39 Nursing
Dia	agnosing Classific	ation	Historie:
Vital Signs	Dm Chf	Docs	Health
Height	72.00 inches		06/06/2007 Questionna
Weight	.00 pounds	Patient Information	06/06/2007 System Rev
BMI	22 %		11 Physical Es
Body Fat BMR	22 % cal/day	C Welcome Letter C Glossary	
vVaist	.00 inches	C What is CHF?	Radiolog
Hips	.00 inches	C How is CHF Treated? C Treatment Options	Procedur
Risk Ratio	.00	C Recovery Prospects	/ / Treatment C
Blood Pressure		C Low Sodium C Potassium in Foods	Treatment
	/ mmHg	O What is Echocardiogram?	CHF Question
Pulse Last Echo		C When To Call Your Doctor C Questions for Your Doctor	Flowshe
Ejection Fraction		C CPET	
Ventricular Dys		C Fluid Restriction C Hyponatremia	
CHF Class	Class II	C CHF and Inactivity	11
Framingham 10-	Yr Risk		Patient In
Mortality Risk			Provider II
Global Cardio Ris	<u>sk</u> 1.4		CHF Prim
		OK Cancel	Treatmen
			Diagnosing A

**Provider Info** – This button will launch a pop-up window that will allow the user to choose from a list of 20 provider-related documents.

CHF Management	Patient Robert Test Jr	Home
	auses Sex M Age 39	Nursing
Diagnosing Classification		Histories
Vital Signs Dm Chf Proc		Health
Height 72.00 inches	06/06/20	Gluestioninalies
vVeight 0.00 pounds BMI	Provider Information	07 System Review
Body Fat 22 %	C CHF Introduction	Physical Exam
BMR cal/day	C Causes of CHF C DHF and Primary Physicians	Radiology
Waist .00 inches Hips .00 inches	C Drug Therapy for CHF C Aggressive Treatment is Necessary	Procedures
Risk Ratio	Pathophysiology of CHF     Diastolic Heart Failure	Treatment Guide
Blood Pressure	C Types of CHF	Treatment Plan
Pulse mmHg	C C-Reactive Protein //	CHF Questionnaire
Last Echo	C Glitazones and Insulin	Flowsheet
Ejection Fraction Ventricular Dvs Systolic		
Ventricular Dys Systolic CHF Class Class II	C Systolic and Diastolic Dysfunction Causes / / /	
Framingham 10-Yr Risk	C Left, Right-Sided Heart Failure	Patient Info
Mortality Risk	C Characteristics of DHF C Causes of SHF	Provider Info
Global Cardio Risk 1.4	Causes of SHF Causes of DHF	CHF Primer
	OK Cancel	Treatment
		Diagnosing Adults
(		

**CHF Primer** -- This button will launch a pop-up window that will allow the user to choose from a list of 14 documents designed to educate in the area of CHF.

CH	HF Manage	ement	Patient Robert	Test Jr	]	Home	<b>_</b>
Goals of Therapy	Differentiating		Sex M	Age 39	]	Nursing	
Diag	nosing C	lassification				Histories	
Vital Signs		Most Recent Labs	Check for New Labs			Health	
Height	72.00 inches	Dm Chf Primedocs		x	6/06/2007	Questionnaires	
vVeight	.00 pounds				6/06/2007	System Review	
<u>BMI</u> Body Fat	22 %	In	formation			Physical Exam	
BMR	cal/day	C Pathophy	ysiology			Radiology	
vVaist	.00 inches	C Patient H	listory Examination			Procedures	
Hips	00 inches	C Causes o	of CHF			Treatment Guide	
<u>Risk Ratio</u> Blood Pressure	1.00		ial Diagnosis ry Studies		11	Treatment Plan	
· · · · · · · · · · · · · · · · · · ·	/ mmHg	C Imaging S C Other Te	Studies		11	CHF Questionnaire	
Pulse			res - Catheterization		11	Flowsheet	
Last Echo Ejection Fraction	11	C Staging o Medical C			//	Flowsheet	
Ventricular Dys	Systolic	🔘 Diastolic	Heart Failure Treatment		11		
CHF Class	Class I	E O Newer T	herapies for Heart Failure Care	•	11		
Framingham 10-Y	<u>'r Risk</u> %	·				Patient Info	
Mortality Risk	1.4	OK	Cancel			Provider Info	
<u>Global Cardio Risk</u>	<u>(</u>					CHF Primer	
					-	Treatment	
						Diagnosing Adults	
4							- <b>-</b>

**Treatment** – This button will launch a single document for printing entitled "**Outpatient Treatment of Systolic Heart Failure**".

**Diagnosing Adults** – This button will launch a single document for printing entitled **"Diagnosis of Heart Failure in Adults**".

				_	
CHF Managemer	IT	Patient Rober			Home
Goals of Therapy Differentiating	Causes	Sex	M Age 39		Nursing
Diagnosing Classificat	ion				Histories
Vital Signs	Most Recent Labs	Check for Nev	v Labs		Health
Height 72.00 inches	Sodium	11	Cholesterol 150	06/06/2007	Questionnaires
Veight _00 pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review
BMI Body Eat 22 %	Chloride	11	HDL		Physical Exam
Body Fat 22 % BMR cal/day	CO2 Glucose	11	LDL		Radiology
Waist .00 inches	BUN	11	Trig/HDL		
Hips .00 inches	Creatinine	11	UA Protein	11	Procedures
Risk Ratio	Calcium	11	тз	11	Treatment Guide
Blood Pressure	Troponin	11	Т4	11	Treatment Plan
/ mmHg	СРК	11	77	11	CHF Questionnaire
Pulse	Digoxin	11	T-Uptake	11	Flowsheet
	PT	11	TSH	11	Flowsheet
Ejection Fraction Help	INR Fibrinogen	11	proBNP		
CHF Class Class II Help	PAI-1	11	Sed Rate		
Framingham 10-Yr Risk %			D-Dimer J		Patient Info
Mortality Risk		Medical History	Labs Over Time	1	Provider Info
Global Cardio Risk 1.4	_			<b>J</b>	CHF Primer
					Treatment
					Diagnosing Adults
					Diagnosing Addits
•					•

# **Treatment Guide Template**

This template guides you through the 12 steps of the standard treatment of CHF. They are:

- 1. Atrial Fibrillation or History of Thromboembolism?
- 2. Diastolic Dysfunction
- 3. Systolic Dysfunction Symptoms of Volume Overload
- 4. Add ACEI & Titrate to Target Dose?
- 5. Ace intolerant
- 6. NYHA Class I HF? (Help)
- 7. NYHA Class II HF? (Help)
- 8. Acceptable Level of functional Status
- 9. Add Digoxin (IF no Bradycardia)
- 10. Acceptable level of functional Status
- 11. Recent NYHA Class IV HF and Class III Or Class IV Symptoms (Help)
- 12. Acceptable Level of Functional Status

Also at the bottom of the template is a Cardiologist Referral Template.

## Step by Step Review of Treatment Guide Template

The first five steps have the following instruction permanently displayed on the template, "Continue to Next Question." After that, this instruction appears according to your response. (See below)

#### Step 1 – Atrial Fibrillation or History of Thromboembolism?

There are two choices:

- No, if the patient does not have atrial fibrillation
- Yes, if the patient does have atrial fibrillation

No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	CHF Guidelines	Return
• No	Diastolic Dysfunction? Continue to Next Question	O Yes	
• Noj	Systolic Dysfunction Symptoms of Volume Overload?	C Yes	
. <u> </u>	Continue to Next Question		
No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes	
• No	Ace Intolerant?	C Yes	
•	Continue to Next Question		

If the answer is, "No," move on to Step 2.

If the answer is "Yes," the following will appear in two columns:

		CHF	Guidelines	Coumadin
O No	Atrial Fibrilation or History of	• Yes	Anticoagulate with Warfarin	
	Continue to Next Question		Patient Refuses Cournadin	Cournadin Refer

#### Column 1 –

- Anticoagulate with warfarin
- **Patient refuses Coumadin** this is a check box which allows you to document the patient's refusal to begin Coumadin.

**Note**: If the patient refuses Coumadin, it is important to document the reason why. When you check the box beside the "Patient Refuses Coumadin," a pick list appears with the following options:

32		CHF	Guidelines	Cournadin
○ No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	• Yes	Anticoagulate with Warfarin	Medrefusal
⊙ No	Diastolic Dysfunction?	C Yes		allergy economical medical religious
⊙ No	Systolic Dysfunction Symptoms of Volume Overload?	C Yes		social Close

#### Column 2 –

There are two buttons which are entitled:

- **Coumadin** this takes you to the **Coumadin Template** which will be discussed elsewhere.
- Coumadin Refer this launches the referral template with which you may send the patient to Coumadin clinic. When you depress this button, you will be asked whether to associate a template or not. Click "This template" and then click OK. An e-mail will appear which can be send to referral. The patient will then be called with an appointment to the Coumadin Clinic.

20		CHF	Guidelines	Cournadin
C No	Atrial Fibrilation or History of	Yes	Anticoagulate with Warfarin	
	Thromboembolism? Continue to Next Question		Patient Refuses Cournadin	Cournadin Refer

To the right of Step 1 is a Return button which will take you back to the Master CHF template,

		CHE	Guidelines		
O No	Atrial Fibrilation or History of	Ves		Cournadin	
CONTRACTOR OF STREET	Thromboembolism?	e res	Anticoagulate with Warfarin	Cournadin Refer	Return
8	Continue to Next Question		Patient Refuses Cournadin	Counterriterer	Return

#### **Step 2 -- Diastolic Dysfunction**

There are two choices:

- No, if the patient **does not** have Diastolic Dysfunction
- Yes, if the patient **does** have Diastolic Dysfunction

**Note**: If the echocardiogram data is filled out at the bottom of **Column I on the Master CHF Template** and if the ventricular dysfunction – either diastolic or systolic – is completed, Step 2 will have been automatically completed before you go to the Treatment Guide.

• No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	CHF C Yes	Guidelines	Return
No	Diastolic Dysfunction?	C Yes		
No	Systolic Dysfunction Symptoms of Volume Overload?	C Yes		
	Continue to Next Question			
⊙ No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes		
• No	Ace Intolerant?	O Yes		
1	Continue to Next Question			

If the answer is, "No," move on to Step 3.



If the answer is, "Yes," the following three instructions will appear:

- 1. Adequate blood pressure control
- 2. Diuretic
- 3. Control Ventricular rate with CCB's



In the third, column there are the following three drugs and/or classes of drugs which can be used in Diastolyic Dysfunction:

- Digoxin
- Nitrates
- Beta-Blockers and ARBs

In a second column are three **Help** buttons which have the following content:

© No Diastolic Dysfunction? Continue to Next Question	• Yes	Diuretic	Help Digoxin Help Nitrates Help Beta-blockers, ARBs
--	-------	----------	--

O No	Diastolic Dysfunction? Continue to Next Question	• Yes	Adequate blood pressure control Diuretic Control ventricular rate with CCB's	Help Digoxin Help Beta-block Help ARBs	Brand Name
------	---	-------	--	--	------------

© №	Diastolic Dysfunction? Continue to Next Question	• Yes	Adequite blood pressure control Divertic Control ventricular rate with CCB's					
Nitrate	25		X					
₫	Vasodilators which lower blood pressure are associates with tachycardia that inhibits diastolic filling and aggravate diastolic CHF.							
			ОК					
Digo	xin		×	<				
4	Digoxin is not recommended with the exception of a patient with atrial fibrillation. On the other hand, it car improve symptoms and decrease hospitalizations in paitents with isolated diastolic dysfunction. (Digitalis Investigation Group Trial)							
(COK								

There is then a link to the Medication Module. For instructions on how to use the Medication Module, <u>Click Here</u>. At each point in the CHF treatment guide that medications are recommended, you will find a link to the Medication Module.

#### Step 3 – Systolic Dysfunction Symptoms of Volume Overload

There are two choices:

- No, if the patient does not have Systolic Dysfunction
- Yes, if the patient does have Systolic Dysfunction

**Note**: If the echocardiogram data is filled out at the bottom of Column I on the Master CHF Template and if the ventricular dysfunction – either diastolic or systolic – is completed, Step 3 will be automatically completed.

		CHF	Guidelines	<b>_</b>
• No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	O Yes		Return
• No	Diastolic Dysfunction? Continue to Next Question	C Yes		
⊙ No	Systolic Dysfunction Symptoms of Volume Overload?	O Yes		
	Continue to Next Question			
⊙ No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes		
⊙ No	Ace Intolerant?	C Yes		
4	Continue to Next Question			

If the answer is, "No," proceed to Step 4. If the answer is, "Yes," the following will appear.

			Add Diuretic; Titrate Eu	volumic State		Brand Name
O No	Systolic Dysfunction Symptoms of Volume Overload?	• Yes	Bumetanide Hydrochlorthiazide Indapamide Metozolone	Bumex HCTZ Lozol Zaroxolyn	0.5 - 10 mg/day 12.5 - 50 mg/day 2.5 - 5 mg/day 5 - 20 mg/day	<b>I</b>
	Continue to Next Question		Patient Refuses Diu	retic		

Beside this list is a link to the Medication Module

Beneath this list is a box entitled **Patient Refuses Diuretic**. The pick list associated with the box is:

C No	Systolic Dysfunction Symptoms of Volume Overload?	Yes	Add Diuretic; Titrate Euvolumic State	0.5 - 10 mg/day 12.5 - 50 mg/day 2.5 - 5 mg/day 5 - 20 mg/day	Brand Name
	Continue to Next Question		Pitient Refuses Diuretic	Medrefusal	×
• No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes		economical medical religious social	
( No	Are Intolerant?	C Ves			Close

# Step 4 – Add ACEI & Titrate to Target Dose?

There are two choices:

		CHF Guidelines		
• No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	© Yes	Return	
• No	Diastolic Dysfunction? Continue to Next Question	© Yes		
• No	Systolic Dysfunction Symptoms of Volume Overload?	C Yes		
	Continue to Next Question			
⊙ No	Add ACEI & Titrate to Target Dose? Continue to Next Question	© Yes		
• No	Ace Intolerant?	C Yes		
	Continue to Next Question			·
•			•	

If you choose, "Yes," the following will appear:

#### Link to Medication Module



#### Patient Refuses an ACE

If the patient refuses an ACE, a pick list for the reasons pops up from which you should select the applicable one.

O No	Add ACEI & Titrate to Target Dose? Continue to Next Question	• Yes	Catopril Capo Enalapril Vası Fosinopril Mon Lisinopril Priniv Attace Ram Patient refuses an ACE	otec 2.5 - opril 5 - 40 /il, Zestril 2.5 - pril 1.25	- 50 mg TID 20 mg BID 0 mg QD 40 mg QD - 10 mg QD edrefusal	Brand Name	
⊙ No	Ace Intolerant?	C Yes		e m re	llergy conomical nedical eligious ocial		
	Continue to Next Question		Г			Close	

#### **Step 5 – ACEI tolerant?**

There are two options:

Answer, "No," if the patient is not intolerant of ACEIs.

Answer, "Yes," if patient had to stop ACEIs due to cough, etc. If you answer that the patient is intolerant of ACEIs, the following appears:

	Continue to Next Question		Return	•
• No	Diastolic Dysfunction? Continue to Next Question	O Yes		
No	Systolic Dysfunction Symptoms of Volume Overload?	O Yes		
	Continue to Next Question			
• <u>No</u>	Add ACEI & Titrate to Target Dose? Continue to Next Question	O Yes		
⊙ No	Ace Intolerant?	C Yes		
	Continue to Next Question			
● No	NIVHA Class I HE? Heln		•	•

# Medication Module link

			Consider HydralazineA	sosorbide Dinitr	rate or ARB	Brand Name
C No	Ace Intolerant?	● Yes	Hydralazine Isosorbide Dinitrate Eprosartan Candesartan Irbesartan Losartan	Teventen Atacand Avapro Cozaar	75 - 300 mg QD - QID 30 - 160 mg QD - TID 400 - 800 mg QD - BID 4 - 32 mg QD - BID 75 - 300 mg QD 25 - 100 mg QD	
	Continue to Next Question		☐ Olmesartan ☐ Telmisartan ☐ Valsartan	Benicar Micardis Diovan	5 - 40 mg QD 20 - 80 mg QD 80 - 320 mg QD	
	Continue to next edestion		Patient refuses an A	ARB		

# Patient refuses an ARB

© No	Ace Intolerant? Continue to Next Question	● Yes	Consider Hydralazine/I Hydralazine Isosorbide Dinitrate Eprosartan Candesartan Irbesartan Olmesartan Telmisartan Yalsartan	Teventen Atacand Avapro Cozaar Benicar Micardis Diovan	rate or ARB 75 - 300 mg QD - QID 30 - 160 mg QD - TID 400 - 800 mg QD - BID 4 - 32 mg QD - BID 75 - 300 mg QD 25 - 100 mg QD 5 - 40 mg QD 20 - 80 mg QD 80 - 320 mg QD 80 - 320 mg QD	Brand Name	
• No	NYHA Class I HF? <u>Help</u>	C Yes			allergy economical medical religious social		
No	NYHA Class II - III HF? Help	O Yes				Close	

# Step 6 – NYHA Class I HF?

**Note**: If the Class of CHF is filled out at the bottom of Column I on the Master CHF Template, Step 6 will be automatically completed.

⊙ No	NYHA Class I HF? <u>Help</u>	O Yes	
• No	NYHA Class II - III HF? <u>Help</u>	C Yes	
● No	Acceptable level of functional status? Continue to Next Question	C Yes	
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes	
© No	Acceptable level of functional status? Continue to Next Question	C Yes	
• No	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	C Yes	

If the patient does not have NYHA Class I HF, proceed to Step Seven.

If the answer is, "Yes," i.e., the patient has NYHA Class I HF, the following will appear



#### Step 7 – NYHA Class II – III HF?

● No	NYHA Class II - III HF? Help Continue to Next Question	C Yes	
• No	Acceptable level of functional status? Continue to Next Question	C Yes	
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes	
⊙ No	Acceptable level of functional status? Continue to Next Question	C Yes	
• No	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	C Yes	
• No	Continue to Next Question Acceptable level of functional status?	C Yes	

**Note**: If the Class of CHF is filled out at the bottom of Column I on the Master CHF Template, Step 6 will be automatically completed.

There are two options:

If, the answer is "No," you move on to Step 8. If the answer is "Yes," the following pops up:

#### Medication Module Link



Patient Refuses a B-Blocker – document the reason why the patient refused.

-			Add a B-blocker; Titrate to target dose	Brand Name
O No	NYHA Class II - III HF? Help	Yes	Metoprolol Metoprolol XL Bisoprolol Zebeta Carvedilol Coreg	12.5 - 200 mg QD 1.25 - 10 mg QD 3.125 - 25 mg BID
	Continue to Next Question		Patient refuses a B-blocker	Medrefusal
• No	Acceptable level of functional status? Continue to Next Question	O Yes		allergy economical medical religious social
⊙ No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes		Close

**Help**—there are help buttons on Step 6, 7 and 10 which give the descriptions of the Four Classes of Congestive Heart Failure. If the Class is checked on the pop-up, it will interact with all other places where the Class of CHF is captured.

• No	Acceptable level of functional Continue to Next Questio					
• No	Add Digoxin (If No Bradycardia Continue to Next Questio					
• No	Acceptable level of functional Continue to Next Questio					
⊙ No	Recent NYHA Class IV HF and Class III or Class IV symptoms Continue to Next Questio					
• No	Acceptable level of functional	status? O Yes				
	Refer to Cardiologis	st				Back To Top
	Status F	Priority	Referring First	Referring Last	Referral	
•						

# Step 8 – Acceptable Level of Functional Status?

If the answer is "Yes," the following appears:



If the answer is, "No," then the following instruction appears, "Continue to Next Question."

## Step 9 – Add Digoxin (if no Bradycardia)

	Continue to next succetor					
● No	Add Digoxin (If No Bradycardia Continue to Next Question					
• No	Acceptable level of functional a					
● No	Recent NYHA Class IV HF and Class III or Class IV symptoms?	Help C Yes				
	Continue to Next Question					
● No	Acceptable level of functional s	status? 🔿 Yes				
	Refer to Cardiologis	t				Back To Top
	Status	riority	Referring First	Referring Last	Referral	
	<b>I</b>		·		Þ	
•						•

If the answer is "Yes," the following appears:

#### Trough level 6 hrs post dose should be monitored for:

- 1. HF worsens or renal function deteriorates
- 2. Signs of toxicity develop (like nausea, vomiting, confusion, visual disturb)
- 3. Dose adjustments are made
- 4. Meds added (e.g. antibiotics, amiodarone, quinidine, vararpamil, anticholinergics)

#### Medication Module link

C No	Add Digoxin (If No Bradycardia) Continue to Next Question	• Yes	<ul> <li>Trough level 6 hrs post dose should be monitored for:</li> <li>1. HF worsens or renal function deteriorates</li> <li>2. Signs of toxicity develop (like nausea, vomiting, confusion, visual disturb, etc)</li> <li>3. Dose adjustments are made.</li> <li>4. Meds added (e.g. antibiotics, amiodarone, quinidine, varapamil, anticholinergics)</li> </ul>	Brand Name
------	--	-------	--	------------

If the answer is "No," the following appears, "Continue to Next Question."

Step 10 – Acceptable level of functional Status?

	Continue to next vacati	on				
• No	Add Digoxin (If No Bradycard Continue to Next Questi					<u>×</u>
No	Acceptable level of functions Continue to Next Questi					
• No	Recent NYHA Class IV HF ar Class III or Class IV symptom	nd Help O Yes s?				
	Continue to Next Questi	on				
© No	Acceptable level of functions	al status? 🖸 Yes				
	Refer to Cardiologi	st				Back To Top
	Status	Priority	Referring First	Referring Last	Referral	
		10 STOTE # 20				
	<b>I</b>		, 			
•						
						•

If the answer is "yes," the following appears:

	C No	Acceptable level of functional status?	• Yes	STOP	1. Continue present management 2. Schedule regular follow-up 3. Manage concomitant cardiac conditions	
--	------	--	-------	------	---	--

If the answer is "no," the following appears, "Continue to Next Question."

	CONTINUE TO NEAR VICESIN						
	Contained to Hold Quode						
	Add Digoxin (If No Bradycard Continue to Next Question		Yes				
• No	Acceptable level of functiona		Yes				
• No	Recent NYHA Class IV HF an Class III or Class IV symptom	nd <u>Help</u> C	Yes				
	Continue to Next Questi	on					
<u> </u>			_				
• No	Acceptable level of functions	al status?	Yes				
	Defente Condicioni						
	Refer to Cardiologi	st					Back To Top
	Status	Priority		Referring First	Referring Last	Referral	
					10.00C		
		100		10	5.6	202	
	•						Þ
•							) I

# Step 11 – Recent NYHA Class IV HF and Class III or Class IV symptoms?

Help – see above

If the answer is, Yes," the following appears

## Medical Module Link

O No	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	• Yes	Consider Spironolactone Brand Name Spironolactone Aldactone 25 - 100 mg QD           Patient refuses spironolactone
	Continue to Next Question		

**Patient refuses** – document the reason for refusal

O No	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	∫⊙ Yes	Consider Spironola Spironolactone Patient refuses s	Aldactone	25 - 100	mg QD I IIII	
	Continue to Next Question		_			allergy	
No	Acceptable level of functional status?	C Yes				economical medical religious social	
-	Refer to Cardiologist						То Тор
	Status Priority		Referring First	Referring Last	Referral	Close	

# Step 12 – Acceptable Level of functional capacity?

	Continue to next warshold					
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes				<u>^</u>
No	Acceptable level of functional sta	atus? O Yes				
• No	Recent NYHA Class IV HF and Class III or Class IV symptoms?‴	Help C Yes				
	Continue to Next Question					
⊙ No	Acceptable level of functional st	atus? O Yes				
	Refer to Cardiologist					Back To Top
	Status Prio	rity	Referring First	Referring Last	Referral	
	1110			in and a set		
	<b>.</b>			1		
•						

If the answer is "yes," the following appears:





1. Continue present management 2. Schedule regular follow-up 3. Manage concomitant cardiac conditions

If no, the following instruction appears, "Refer to Cardiologist."

	Continue to next edestion					
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes				
€ No	Acceptable level of functional status? Continue to Next Question	C Yes				
● No	Recent NYHA Class IV HF and Class III or Class IV symptoms?	O Yes				
	Continue to Next Question					
• No	Acceptable level of functional status?	C Yes				
	Refer to Cardiologist					Back To Top
	Status Priority		Referring First	Referring Last	Referral	
	•				<u> </u>	
•						▼ ▶

## **CHF Treatment Plan Template**

Across the top of this template are links to:

- Lipids
- Diabetes
- Metabolic Syndrome
- Weight Management
- Hypertension

Each of these conditions contributes to the development and/or worsening of CHF. The effective treatment of CHF includes the effective management of each of these five areas.



Down the left hand side of this template there are the following buttons and/or links:

- Hydration
- Seven Steps to Success
- Focus of Treatment
- Evaluation
- General Measures
- Fluid Management
- Weight Loss
- Exercise
- Smoking Cessation
- Lung Congestion
- CHF compliance
- Meds Precipitating CHF
- Additional Management
- Follow up Instructions

• CHF Compliance E-Mail

	CHF Tre	atment Plar	ı		<u>_</u>
Hydration	Lipids Diabetes Meta	abolic Syndrome Veid	aht Management Hyp	ertension	
Seven Steps to Success Focus of Treatment Evaluation General Measures	CHF Status	O Improved O No	Change O Worse		Return Document Follow-Up Doc
Fluid Management Weight Loss Info Exercise Smoking Cessation Lung Congestion CHF Compliance Meds Precipitating CHF Additional Management Follow Up Instructions CHF Compliance Email	BMP proBNP CMP CPK Digoxin Lipid Panel w/LDL Radiology EKG	Potassium PT/INR Thyroid Profile Troponin Urinalysis Venipuncture Chest PA/Lat Chest 1 View Medication In	Flu Shot     Dx 1     Dx 2     Dx 3	Pneumovax	
Referrals (double-click to add) Priority Referring First Referring	Last Referral Bra		tk to add) Dose 25MG 100 unit p 100 unit p	Follow Up	Information Echocardiography Relapse Control Take Care Self Lifestyle Changes
<b>(</b>					v Þ

Four of these are explained in tutorials linked below:

- <u>Hydration</u>
- Weight Loss
- Exercise
- Smoking Cessation

#### The other eleven are functions which are:

- 1. Educational for the provider
- 2. Educational for the patient
- 3. Evaluational as to how the patient's care for CHF is proceeding
Each of the eleven **CHF-Template-Plan-Template Pop-ups**, which are specific to the CHF templates, will be explained below.

• **Hydration** – because dehydration and azoemia are such common problems in patients with CHF, this link to the **Hydration Evaluation Template** allows for you to document the state of the patient's hydration while treating their volume overload due to CHF.

Hyd	Iration Assessment	
Setting	C Clinic C Nursing Home C Hospital C Hospital Discharge	
Increased Risk of Dehydration  Recent Infection  Febrile Temp Recent Weight Loss Impaction Decreased Appetite Change in Mental Status Paralysis Inability to Feed Self Diabetes Mellitus On Diuretics Hypoalbuminemia Age over 60 Nursing Home Resident Nausea Nausea Nausea Nausea Unable to turn and position	Hospital O Hospital Discharge Physical Evidence of Dehydration Skin Turgor Buccal Mucosa Urine Output < 30 cc/hr Orthostatics Pulse / Lying / Standing Drop greater than 20 mmHg Drop less than 20 mmHg	Return         Print         Help Documents         Degree of Dehydration         Electrolytes and Osmolarity         Ethical Issues about Hydration         Factors Affecting Creat, BUN         Fluid Requirements         Osmolality Norms         Osmolality Theory         Renal Physiology and Hydration         Signs of Dehydration
Metabolic & Chemical Analysis of         Urine Specific Gravity         Glucose         Sodium         Potassium         Chloride         HCO <sub>3</sub>	Hydration     Calculate       BUN     Serum Osmolality       Creatinine     Serum Osmolarity       BUN/Creat Ratio     Info       Check for New Labs     Info       Laboratory Dates     Est. Creat Clearance       C Good     Marginal       Adequate     Dehydrated	
•		•

• Seven Steps to CHF Treatment Success – this document allows you to review seven steps which are crucial to the success of treating CHF. These seven steps are imperative to effective treatment of CHF.

### Dm Chf Sevensteps

Seven Steps to CHF	Treatment Success
<ul> <li>Control Risk Factors         <ul> <li>hypertension</li> <li>eliminating alcohol use</li> <li>diabetes</li> <li>CAD</li> </ul> </li> <li>A CE Inhibitor of Angiotensin Receptor Blocker</li> <li>All patients with heart failure should be taking an angiotensin-receptor blocker. In the absence of contraindications, an ACE inhibitor is preferred. In most patients, physicians should consider adding a beta blocker to ACE-inhibitor therapy.</li> <li>Spironolactone</li> <li>Matients with severe heart failure, spironolactone is a useful addition to baseline drug therapy, as is carvedilol (Coreg) (substitute carvedilol if patient is aready taking a beta blocker).</li> <li>Actobic Exercise</li> <li>Matients with stable heart failure should be failed be the state as a blocker).</li> </ul>	<ul> <li>Digoxin therapy may reduce the likelihood of hospitalization but does not reduce mortality. It must be monitored closely, with a target dosage level of 0.5 to 1.1 mg per mL.</li> <li>Directic and Sodium Intake</li> <li>Symptoms may be controlled with the use of diuretics and restricted dietary sodium.</li> <li>Datient Education</li> <li>Matient education, with the patient's active participation in the care, is a key strategy in the anagement of heart failure.</li> <li>Periodic follow-up between scheduled office visits, which is essential in the long-term management of heart failure.</li> <li>i elephone calls from the office nurse</li> <li>i maintenance of daily symptoms</li> <li>i weight diary</li> <li>i participation in a disease management program</li> </ul>

• Focus of CHF Treatment – this pop-up documents the four sites of action of CHF treatment: preload reduction, afterload reduction, inhibition of RAAS system and Inotropic support.

×



### • Evaluation

This is an interesting tool for evaluating the patient with CHF. By following a series of questions with yes and no answers, you are led through a differential diagnosis of the patient with possible CHF.

This pop-up is entitled, "Evaluation of Heart Failure."

The process begins with the following instruction, "Begin answering the questions to the left. Additional questions and/or recommendations will appear."

E∨aluati	ion of Heart Failure	-
Begin answering the questions to the left	. Additional questions and/or recommendations will appear.	
Dyspnea present? O Yes O No	Return	
Medical History anemia hypertension cardiotoxic medications infectious disease chest irradiation peripheral vascular disease colagen vascular disease pheochromocytoma CAD rheumatic fever diabetes mellitus STDs hemochromatosis thyroid disease hypercholesterolemia valvular heart disease Social History	Physical Exam       pallor         tachycardia       pallor         bronze skin       pericardial rub         cardiac arrhythmia       pulmonary rales         dependent edema       third heart sound         displaced cardiac apex       weight loss or gain         elevated blood pressure       abnormal deep tendon reflexes         heart murmur       diminished peripheral pulses or arterial bruits         joint inflammation       hepatomegaly or hepatojugular reflux         jugular venous distention       thyromegaly or thyroid nodule	
alcohol     international travel     drugs	Laboratory Tests           ANA         Liver Function Test           BMP         Metanephrines	
Family History         CAD       skeletal myopathy         cardiomyopathy       cardiac conduction abnormality         sudden death       sudden death	CMP       Rheumatoid Factor (if connective tissue disease suspective tissue disease suspective)         Electrolyte Panel       Serum Ferritin         HIV (in high risk patients)       TSH         Lipid Panel       Urinalysis         CBC       Viral Titers (if patient had recent viral infection)	ectei
•		•

The first question is, **"Dyspnea Present?"** if the answer is, "no," the recommendation is **"consider other causes."** If the answer is "yes," the recommendation is **Obtain ECG and chest radiograph."** 

Begin ans		on of Heart Failure . Additional questions and/or recommendations	will appear.
Dyspnea present?	🔍 Yes 🔍 No	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph ab	normal? O Normal O Abnormal		

This second question asks, **"ECG or chest radiograph abnormal?,"** if the answer is normal, the recommendation is, **"consider other causes."** If the answer is **"abnormal**," the recommendation is, **"obtain echocardiogram."** 

Begin answering		of Heart Failure litional questions and/or recommendations will app	ear.
Dyspnea present?	• Yes • No	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph abnormal?	C Normal	Obtain echocardiogram.	
Echocardiogram results?	O Normal O Abnormal O Technically Unsatisfactory		

The third question is **,"echocardiogram results?"** If the response is, "normal," the recommendation is **"consider other causes."** If the response is "abnormal," the recommendation is **"more detailed history, physical and laboratory testing. See below."** 

	•	litional questions and/or recommendations will appear.	
Dyspnea present?	• Yes • O No	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph abnormal?	C Normal 💿 Abnormal	Obtain echocardiogram.	
Echocardiogram results?	C Normal C Abnormal	More detailed history, physical, and laboratory testing. See below.	

A second option under the third question is related to the echocardiogram and states, "Technically unsatisfactory." If the echo is considered "technically inadequate," the recommendation is "obtain radionucleotide scan."

The fifth question is **"Radionucleotide scan results."** If the answer is normal, the recommendation is, **"consider other causes."** If the answer is "abnormal," the recommendation is **"more detailed history, physical, and laboratory testing. See below."** 

Begin answering		of Heart Failure itional questions and/or recommendations will app	ear.
Dyspnea present?	• Yes C No	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph abnormal?	C Normal 💿 Abnormal	Obtain echocardiogram.	
Echocardiogram results?	C Normal C Abnormal Technically Unsatisfactory	Obtain radionucleotide scan.	
Radionucleotide scan results?	O Normal O Abnormal		

Beneath this series of questions is a section which includes:

Dyspnea present?	Yes U No	Obtain ECG and chest	radiograph.
ECG or chest radiograph abnormal?	C Normal 💿 Abnormal	Obtain echocardiogram	n.
Echocardiogram results?	C Normal C Abnormal Technically Unsatisfactor	Obtain radionucleotide	e scan.
Radionucleotide scan results?	C Normal C Abnormal		
Cardiotoxic medications infer chest irradiation perij collagen vascular disease pher CAD rhet diabetes mellitus STD hemochromatosis thyr hypercholesterolemia valv Social History alcohol inter drugs Family History CAD skel	ertension ctious disease pheral vascular disease ochromocytoma umatic fever bs roid disease vilar heart disease rnational travel letal myopathy diac conduction abnormality	Physical Exam acnycardia bronze skin cardiac arrhythmia displaced cardiac apex elevated blood pressure heart murmur joint inflammation jugular venous distention aboratory Tests ANA BMP CMP Electrolyte Panel HIV (in high risk patients) Lipid Panel CBC	<ul> <li>pallor</li> <li>pericardial rub</li> <li>pulmonary rales</li> <li>third heart sound</li> <li>vveight loss or gain</li> <li>abnormal deep tendon reflexes</li> <li>diminished peripheral pulses or arterial bruits</li> <li>hepatomegaly or hepatojugular reflux</li> <li>thyromegaly or thyroid nodule</li> <li>Liver Function Test</li> <li>Metanephrines</li> <li>Rheumatoid Factor (if connective tissue disease suspecte)</li> <li>Serum Ferritin</li> <li>TSH</li> <li>Urinal ysis</li> <li>Viral Titers (if patient had recent viral infection)</li> </ul>
1			

Each of these categories gives the opportunity to review and think about pertinent issues related to CHF, its diagnosis and evaluation. Some of the information will have already auto-populated from other parts of the EMR

The laboratory tests listed on this pop-up, when checked, will appear either on the CHF Plan template, or on the Laboratory Charge Posting template, if the lab test is not listed on the Plan template.

**Note**: If you check in the review of this **Evaluation** template that a lab test needs to be ordered and if that lab test is not on the CHF Plan template, it will be necessary to:

- Go to the Master GP Lab Charge Posting template
- Uncheck the lab test(s) which were placed there from the CHF Evaluation template
- Select the ICD-9 Codes
- Re-select the lab tests which you indicated you want to order from the CHF Evaluation template
- Click Submit to charge posting.



cute Diagonses	Clear Diagnosis Field		ATORY ORGERS rdering Provider folly James	Submit E-mair	Common Ne	eurology Orders
	Acetominophen ACTH Albumin	Diagnosis Cod	e Mstr			×
	Aldosterone, Serum	Description		Icd9cm Code Id	User Description	
	Alkaline Phosphate Iso	AA Branci	hed Chain Dis Maple Syrup Urine	2703	RxHCC	
	Allergy, Adult Food	AA Disord	ers Specified	2708	RxHCC	
	Allergy, Childhood		ers Unspecified	2709	RxHCC	
			lomocysteine	2704	RxHCC	
	Amiodarone					1000
ronic Diagnoses	Amitriptyline		ni Syncrome	2700	RxHCC	
Abd Pain Rebound Tenc	Amylase		ne Metabolism Disturbance	2705	RxHCC	
Hyperten Benign Esser		AA Metab	olism Disorder	2702	RxHCC	
Cardiac, Coronary Occl	Apo A1	AA Pheny	lketonuria	2701	RxHCC	
(	🗖 Аро В	🔲 🛛 🗛 Straigh	nt-chain Glucoglycinuria	2707	RxHCC	
AA Metabolism Disorder	Apo E (Alzheimers)	AA Urea (	Cycle Metabolism Distubance	2706	RxHCC	
Abn Acid/Base Disorde	AST	Abd Pain		78906		
Abit Aciu/Base Disorde	E B12		Generalized	78907		
	Beta 2 Microglobulin Bilirubin, Direct					
	BMP	Abd Pain I		78904		
	BMP, Fasting	Abd Pain I	LUQ	78902		
	E BNP	Δhd Pain I	Periumbilical	78905		
(	🗖 BUN	Refresh	1		ОК	Cancel
	<u>Г</u> СЗ	<u> </u>	]			Cancer
, 	C4		<b>-</b>	<b>—</b>		<b>—</b>
	CA 125	EBV AB	Influenza			Urine, Alk
	CA CEA	Electrolyte Parlel			, Cournadin Clinic	Urine, Cri
	Calcium, Ionized	Erythropoletin	Insulin, Fasting		, coumadin clinic	Urine, So
mments	Carbamazepine	ESR	Keppra	Retic C	Count	UTSH
nsert special instructions	CBC	Estradiol	Г КОН		atoid Factor	Valproic .
en click email button.)	E Ceir Count, Body Fluid	Factor V Leiden		RPR w	/Reflex Titer	VAP Test
	Cell Count, Synovial	E Ferritin	드내	🗌 Rubella		📃 Varicella,
	CK, Isoensymes	Folic Acid	Librium	Rubella		🗌 🗌 Varicella,
		Fructosamine			Analysis	Venipun
	ID CPK	I FSH	Lipid Panel	Sickle	Cell Screen	VMA, Rar

# General Measures

This pop-up reviews seven conditions which are closely linked with CHF which are reviewed on this pop-up. They are:

## a. Blood Pressure

The patient's blood pressure will be automatically posted to this pop-up. If it is elevated, the following recommendation will appear, "Better blood pressure control (systolic 110-120 mmHg) is needed. Use hypertension templates and adjust medications."

## b. Hyperlipidemia

- Cholesterol/HDL Ratio
- Triglyceride/HDL Ratio

The patient's cholesterol/HDL Ratio will be automatically posted. If it is above 4, the recommendation will state, "**Improved lipid management needed**."

The patient's Triglyceride/HDL Ratio will be automatically posted. If it is above 2, the recommendation wills state, "**Insulin resistance should be evaluated**."

### c. Smoking Cessation

• Does the patient smoke

If the patient's history indicates tobacco use, the following recommendation will appear, "Discuss smoking cessation with the patient."

- d. Alcohol use Print patient (info)
- Does the patient drink alcohol? Yes No

If the patient's history indicates alcohol use, the following recommendation will appear, "Continued alcohol use in the face of CHF is harmful."

### e. Illicit Drug Use

• Does the patient use illicit drugs? Yes No

If the patient's medical history indicates whether drugs are used or not, it will be automatically posted here. If drugs are used, the following recommendation will appear, "Increasingly illicit drug use is appearing as a cause of CHF, particularly with inhaled cocaine and stimulants."

- f. Diabetes
- Hemoglobin A1C

The patient's Hemoglobin A1C is automatically posted in the box labeled as above. If the value is abnormal the following recommendation appears, "**Optimal control of CHF requires tighter control of hyperglycemia**."

g. Thyroid

- T3
- TSH

The patient's Thyroid values are automatically posted in the boxes labeled as above. If the values are abnormal, the following recommendation appears, "The heart is very dependent on thyroid for proper function. Attention should be given to controlling the patient's thyroid function."

Measures Recommended Action
The heart is very dependent on thyroid for proper function. Attention should be given to controlling the patient's thyroid function.
Cancel

• Fluid Management

This pop-up displays the following options, which can be selected for patient treatment:

Dm Chf Planfluid	×
Fluid Management	
<ul> <li>Restrict daily sodium intake to 2-3 grams per day</li> <li>Daily weight measurement to asses for fluid retention</li> <li>Fluid restriction (to correct clinically important hyponatremia)</li> <li>Strictly avoid high fluid intake (e.g. &gt; 3 liters per day)</li> </ul>	
Information Select the document that you would like to view and click OK.	
C Low Sodium C When To Call Your Doctor C Hyponatremia C Facts for Fluid Retention	
OK Cancel	

• Lung Congestion

The first step in treating DHF patients is to reduce lung congestion. You do that by lowering pulmonary (lung) pressure. This has 3 steps:

- 2. Reduce heart size.
- 3. Make the heart's chambers work together as a team.
- 4. Slowing the heart rate.

# Lung Congestion

The first step in treating DHF patients is to reduce lung congestion. You do that by lowering pulmonary (lung) pressure. This has 3 steps:

#### 🗌 1. Reduce heart size.

At first, heart size can be reduced by restricting fluid and sodium intake, by dialysis or filtering the blood, plasmapheresis, and diuretics. Relaxing (dilating) the blood vessels using nitro or morphine is effective but should be started at low doses to avoid low blood pressure. Low blood pressure can be a real problem in DHF patients. Long-term treatment should include small to moderate diuretic doses, mild doses of long-acting nitro, and restricted sodium intake. Aldactone (spironolactone) may be effective long-term because it suppresses the RAS. ACE inhibitors and ARBs reduce fluid retention and oxygen demand.

#### 2. Make the heart's chambers work together as a team.

The second step in lowering pulmonary pressure is to keep the heart's upper chambers (atriums) beating properly. Atrial fibrillation is poorly tolerated in DHF patients because it increases diastolic pressures, causing lung congestion and low blood pressure. In patients with a-fib, restoring normal rhythm should be a priority. Patients who need a pacemaker should have atrial pacing as well as ventricular pacing.

#### ☐ 3. Slowing the heart rate.

The third step in lowering pulmonary pressures is to slow the heart rate. This gives the heart more time to relax so it can fill with blood. Fast heart rate is poorly tolerated in DHF patients because rapid heart rate:

- 1. increases the heart's oxygen demand and reduces blood flow to the heart, causing ischemia even without CAD
- 2. prevents full relaxation of the heart muscle, which raises pressure and reduces the heart's flexibility
- 3. shortens the heart's relaxation period, making it incomplete, which reduces the amount of blood pumped per beat

#### Select this box and click OK to view and print this information.



• CHF Compliance

The pop-up launched from this button is entitled, "**Factors that may precipitate relapses in patients with pre-existing CHF.**" This is a quick and good review of the potential causes for patient's not responding to treatment for CHF. There is an option to check mark any issue relevant for the care of the patient.

×

Factors that may precipitate relapse	s in patients with pre-existing CHF
<ul> <li>Lack of treatment compliance</li> <li>Myocardial infarction</li> <li>Angina pectoris or painless myocardial ischaemia</li> <li>Alcohol consumption</li> <li>Cardiac arrhythmias</li> <li>Inappropriate medical treatment</li> <li>Infections</li> <li>Anemia</li> </ul>	<ul> <li>Pulmonary embolism</li> <li>Thyroid disease</li> <li>Pregnancy</li> <li>Physical, dietary, fluid, and environmental excesses</li> <li>Emotional stress</li> <li>Systemic hypertension</li> <li>Smoking</li> </ul>
OK	Cancel

• Medications Precipitating CHF

The pop-up launched from this button is entitled, "Medications Which May

**Precipitate/Exacerbate Heart Failure.**" A quick review of the patient's medications and this list will help in making certain that the treatment of another condition is not fighting against the treatment of CHF.

Negative Inotropes	Medications with Cardiotoxic Properties
Antiarrhythmics	Chemotherapeutic Agents
🔲 disopyramide (Norpace)	🗖 doxorubicin
🔲 flecainide (Tambocor)	🗖 daunorubicin
Beta Blockers	Cyclophosphamide
🔲 pindolol (Blocarden, Corgard, Sectral, Visken)	Cocaine
acebutolol	Amphetamines
Calcium Channel Agonists	Agents Causing Sodium and Water Retention
🗖 verapamil	Estrogen
🔲 diltiazem	
nifedipine (Adalat CC)	☐ qlucocorticoids
felodipine (Plendil)	□ salicylates (high-dose)
Expansion of Blood Volume	Drugs with high sodium content (carbenicillin, ticarcil
hydralazine	
minoxidil (Loniten)	

Additional Management

This is a list of important, but ancillary issues for the effective and excellent treatment of CHF. There is an option for check marking the ones related to this patient.

×

Dm Chf Planmng	×
Additional Management	
<ul> <li>✓ Flu vaccination every fall         <ul> <li>Last Flu Shot</li> <li>05/30/2007</li> <li>Pneumovax every 5 years             <ul></ul></li></ul></li></ul>	
OK Cancel	

• Follow Up Instructions

This is a list of instructions which are automatically checked and placed on the patient's CHF follow-up note.

Dm Chf Planfollow	×
Follow Up Instructions	
<ul> <li>Blood Pressure Diary</li> <li>SETMA CHF educational booklet given to patient or family</li> <li>Compliance encouraged</li> <li>Adherence to non-pharmacological measures</li> <li>Adverse effects of therapy discussed</li> <li>Blood in stool</li> <li>Blood in urine</li> <li>Chest pain</li> <li>Decreased appetite</li> <li>Easy bruising</li> <li>Fatigue</li> <li>Light headiness</li> <li>Muscle cramps</li> <li>Shortness of breath</li> </ul>	
OK	

# • CHF Compliance E-mail

This is a link which launches an **electronic tickler file**. When activated, the following steps are taken:

- A pop-up appears which asks "Attach Patient's Document." The option entitled "This template" should be selected.
- Then click OK.
- An e-mail appears which has the following text automatically placed:
- Please call Test IBM Serv AAA at 4098354550 to remind them to: (1) weigh daily and call if more than 3 pounds is gained, (2) take all medications as prescribed, (3) avoid salt in diet, (4) keep appointments, (5) follow their CHF exercise prescription, (6) review their CHF follow-up document, and (7) review their CHF patient education booklet. This patient should be called at least once a week and the telephone call documented in the EMR.
- Send the e-mail to your nurse and/or your unit clerk. You can also copy it to yourself.
- Before clicking send, go to "Options."
- On the Options pop-up select, "Do not send delivery before," and select a date one week, two weeks or whatever appropriate interval the patient's condition warrants the telephone follow-up.
- Then click send.

This electronic tickler file will sit on the server until the appointed date, at which time it will appear on the addressee's desktop. The follow-up telephone call can be made; the information can be given; the contract can be documented; and if appropriate, another electronic tickler file for one week, etc. can be created to remind you to follow-up with this patient.

	CHF Treatment Plan	
Hydration	Lipids Diabetes Metabolic Syndrome Weight Management Hypertension	
Seven Steps to Success		Return
Focus of Treatment	CHF Status 🔘 Improved 🔍 No Change 🔿 Worse	Document
Evaluation	Ordering Provider Holly James	Follow-Up Doc
General Measures	Laboratory	
Fluid Management	BMP Potassium Flu Shot Pneumovax	
VVeight Loss	Info proBNP P Attach X	
Exercise	CMP T Attach Patient's Document	
Smoking Cessation		
Lung Congestion	Lipid Panel w/LDL V	
CHF Compliance	Radiology  © No Attachment	
Meds Precipitating CHF	Info EKG Che C This Template	
Additional Management	Che C Template	
Follow Up Instructions		
CHF Compliance Email		
Referrals (double-click to	padd) Medication:	Information
Priority Referring First	Referring Last Referral Brand Name	Echocardiography
	HYDROXY2	Relapse Control Take Care Self
	apidra 100 unit p	
	apidra 100 unit p	Chestyle Changes

At the top of the middle section of the CHF Plan Template, there is a place to document the CHF Status of the patient. The options are:

<u>Hydration</u>	6					Hypertension	Patron
Seven Steps to Success		1	CHF Status	s 🔿 Improved 🔿	No Change 🛛 🔿 W	(oron	Return
Focus of Treatment				•	No change C W	orse	Document
Evaluation		Order	ring Provid	er Holly	James		Follow-Up Doc
General Measures		Labor	ratory		Immunizatio	ons	
Fluid Management			IMP	🔲 Potassium	🔲 Flu Shot	🗖 Pneumovax	
Weight Loss	Info		roBNP				
Exercise			:MP :PK	Thyroid Prof	Dx 1		
Smoking Cessation			iqoxin	Urinalysis	Dx 2		
Lung Congestion			ipid Panel w		Jre Dx 3		
CHF Compliance		Radi	iology		0.4	mit Charge Posting	
Meds Precipitating CHF	Info		EKG	🔲 Chest PA/Lat	Sur	mit Charge Posting	
Additional Management				🔲 Chest 1 View			
(Follow Up Instructions)							
CHF Compliance Email				Medication	Info		
Referrals (double-clic	k to add)		3	Medications (double-	click to add)	Follow Up	Information
Priority Referring First	Referring	Last	Referral	Brand Name	Dose	•	Echocardiography
				HYDROXYZINE HCL	25MG		Relapse Control
a des	10			apidra	100 unit p	Education Booklet	Take Care Self
				apidra	100 unit p		Lifestyle Changes
•			•		<u>•</u>		

Beneath the Status in the middle section of the CHF Plan Template is a list of Laboratory studies, procedures and Immunizations which can be ordered and charge posted from the CHF Plan Template.

	CHF	Treatment Pla	an		
Hydration	Lipids Diabetes	Metabolic Syndrome	eight Management Hy	pertension	
Seven Steps to Success					Return
Focus of Treatment	CHF Stat	us 🔿 Improved 🔿	No Change 🛛 🔿 Wor:	se	Document
Evaluation	Ordering Provi	der Holly	James		Follow-Up Doc
General Measures	Laboratory		Immunization		
Fluid Management	E BMP	🔲 Potassium	Flu Shot	Pneumovax	
Weight Loss Info	proBNP	E PT/INR			
Exercise		Thyroid Prof	Dx 1		
Smoking Cessation	CPK	🗌 Troponin 🔲 Urinalysis	Dx 2		
Lung Congestion	Lipid Panel				
CHF Compliance	Radiology		Cuburi	t Charge Posting	
Meds Precipitating CHF Info	EKG	🔲 Chest PA/Lat	Submi	Charge Posting	
Additional Management		🔲 Chest 1 View			
(Follow Up Instructions)					
CHF Compliance Email		Medication	Info		
Referrals (double-click to add	J)	Medications (double-	click to add)	Follow Up	Information
Priority Referring First Refe	rring Last Referral	Brand Name	Dose 🔺	1	Echocardiograph
		HYDROXYZINE HCL	25MG		Relapse Control
N. 125 / 129		apidra	100 unit p	Education Booklet Giv	en Take Care Self
	Þ	apidra	100 unit p 💌	11	Lifestyle Change
					•

Once the ICD-9 Code has been added and once the lab studies or procedures have been selected, click on the "Submit Charge Posting" button.

The right side of the CHF Plan has three buttons:

	CHF	Treatment Pla	an		-
Hydration	Lipids Diabetes	Metabolic Syndrome W	eight Management Hy	pertension	
Seven Steps to Success					Return
Focus of Treatment	CHF State	us C Improved C I	No Change 🛛 🔿 Wor	se 📻	Document
Evaluation	Ordering Provi	der u.u.	lane and the second		
General Measures		Holly	James		ollow-Up Doc
Fluid Management	Laboratory BMP	Potassium	Immunization Flu Shot	s	
Weight Loss Info	proBNP		I FIG SHOL	1Prieumovax	
Exercise	CMP	Thyroid Profi			
Smoking Cessation		🔲 Troponin	Dx 1		
Lung Congestion	Digoxin	// Urinalysis ///LDL // Venipunctu	Dx2		
CHF Compliance	Radiology	wiebe i vempunett	ne Dx3 j		
Meds Precipitating CHF Info		Chest PA/Lat	Submi	t Charge Posting	
Additional Management		Chest 1 View			
[Follow Up Instructions]					
CHF Compliance Email		Medication	Info		
		Medications (double-	click to add)	Follow Up	Information
Referrals (double-click to add)					E L L L
Referrals (double-click to add)	a Loct Referrel		Dooo	7	Echocardiography
Referrals         (double-click to add)           Priority         Referring First         Referring	g Last Referral	Brand Name	Dose		Relapse Control
	g Last Referral				
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG	Education Booklet Given	Relapse Control
	g Last Referral	Brand Name HYDROXYZINE HCL apidra	25MG 100 unit p		Relapse Control Take Care Self
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG 100 unit p	Education Booklet Given	Relapse Control Take Care Self
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG 100 unit p	Education Booklet Given	Relapse Control Take Care Self
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG 100 unit p	Education Booklet Given	Relapse Control Take Care Self
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG 100 unit p	Education Booklet Given	Relapse Control Take Care Self
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG 100 unit p	Education Booklet Given	Relapse Control Take Care Self
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG 100 unit p	Education Booklet Given	Relapse Control Take Care Self
Priority Referring First Referring		Brand Name HYDROXYZINE HCL apidra apidra	25MG 100 unit p	Education Booklet Given	Relapse Control Take Care Self

Across the bottom of the CHF Plan Template there are the following:

- <u>Referral</u> Link
- <u>Medications Module</u> Link
- Follow-up Visit documentation
- Education Booklet Given Documentation
- **Information** these are printable documents:
  - 1. Echocardiography
  - 2. Relapse Control
  - 3. Take Care Self
  - 4. Lifestyle Changes

## **Medication Information**

Above the medication Module Link, there is a button entitled "**Medication Info.**" Depressing this button launches a pop-up entitled CHF Medications.

CHF Treatment Plan	<b>_</b>
Hydration Lipids Diabetes Metabolic Syndrome Weight Management Hypertension	
Seven Steps to Success  CHF Status C Improved C No Change C Worse	Return
	Document
Evaluation Ordering Provider Holly James	Follow-Up Doc
Laboratory Immunizations	
Fluid Management         BMP         Potassium         Flu Shot         Pneumovax           Weight Loss         Info         proBNP         PT/INR	
Exercise CMP Thyroid Profile	
Smoking Cessation CPK Troponin Dx 1	
Digoxin         Urinalysis         Dx 2           Lung Congestion         Lipid Panel w/LDL         Venipuncture         Dx 3	
CHF Compliance Padiology	
Meds Precipitating CHF Info EKG Chest PA/Lat	
Additional Management Chest 1 View	
[Follow Up Instructions]	
CHF Compliance Email Medication Info	
Referrals (double-click to add) Medications (double-click to add) Follow Up	Information Echocardiography
Priority Referring First Referring Last Referral Brand Name Dose	Relapse Control
HYDROXYZINE HCL 25MG	Take Care Self
apidra 100 upit p	Given Lifestyle Changes
•	<b>•</b>

By selecting a category of medications and then selecting a drug in that category, it is possible to review on line the following:

- Adult Dose
- Pediatric Dose
- Pregnancy Warning
- General Information
- Interactions
- Precautions
- Contraindications

for each of the drugs used in the treatment of congestive heart failure.

Dm Chf Medics					×
		CHF Med	dications		
1. Select a drug category.					
O ACE Inhibitors O A	ngiotensin Receptor Bloc	kers 🔿 Beta-A	drenergic Blockers 📀	Calcium Channel Blockers 🔘 D	)iuretics
C Human B-Type Natriu	iretic Peptides 🛛 🔿 Inc	tropic Agents	C Phosphodiesteras	se Enzyme Inhibitors 🛛 🔿 Vas	odilators
2. Select a drug.		3. View the a	vailable information.	r Anna an an anna an	
			y, click in a box and us formation in the boxes b	e the arrow keys to scroll throug below.)	h
		General Infor	mation		
Adult Dose	Interactions	I	Precautions	Contraindication	s
Pediatric Dose					
Pregnancy					
		ок	Cancel		

m Chf Medics				2
	(	CHF Me	dications	
1. Select a drug category.				
ACE Inhibitors     ACE Inhi			Adrenergic Blockers 🔘 Calcium Cha 🔘 Phosphodiesterase Enzyme Inf	
2. Select a drug.		3. View the	available information.	
Captopril (Capoten) Enalapril (Vasotec)			ary, click in a box and use the arrow k nformation in the boxes below.)	eys to scroll through
C Quinapril (Accupril) C Lisinopril (Prinivil, Ze	tviD	General Info	ormation	
<ul> <li>Eisinoprii (Prinkii, 20</li> <li>Ramprii (Altace)</li> <li>Fosinoprii (Monoprii)</li> </ul>			ersion of Ang I to Ang II (a potent vasocons ma renin and a reduction in aldosterone sec	
Adult Dose	Interactions		Precautions	Contraindications
10 mg/d PO initially; may increase to 20-40 mg/d qd or divided bid	NSAIDs may reduce hyp effects of ACE inhibitors inhibitors may increase d and allopurinol levels; rift decreases ACE inhibitor probenecid may increase	; ACE igoxin, lithium, ampin levels; ACE inhibitor	Category D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe CHF	Documented hypersensitivity; renal impairment, angioedema
Pediatric Dose	levels; hypotensive effe inhibitors may be enhand			
Not established	concurrently administere			
Pregnancy				
D - Unsafe in pregnancy				

	CHF M	edications	
1. Select a drug category.			
🔿 ACE Inhibitors 🕤 Ang	iotensin Receptor Blockers 🔘 Bet	a-Adrenergic Blockers 🔘 Calcium Cha	nnel Blockers 🔘 Diuretics
C Human B-Type Natriure	tic Peptides 🛛 🔘 Inotropic Agents	s 💿 Phosphodiesterase Enzyme Inł	nibitors 🔿 Vasodilators
2. Select a drug.	3. View th	e available information.	
Milrinone (Primacor)		sary, click in a box and use the arrow k I information in the boxes below.)	eys to scroll through
	General In	formation	
	increased ca demonstrate		none to dobutamine have s in preload and afterload and ises in myocardial oxygen
dult Dose	Interactions	Precautions	Contraindications
50 mcg/kg IV loading dose over 10 min, followed by continuous infusion at 0.25-1.0 mcg/kg/min; titrate to maintain adequate systolic blood pressure and cardiac output	Precipitates in presence of furosemide	Monitor fluids, electrolyte changes, and renal function during therapy; excessive diuresis may increase potassium loss and predispose digitalized patients to arrhythmias (correct hypokalemia with potassium supplementation prior to treatment); slow rates or stop infusion in patients showing excessive decreases in blood	Documented hypersensitivity; obstructive hypertrophic cardiomyopathy

## **CHF** Questionnaire Template

This is a 21-question tool which scores the functional capacity of a patient with CHF. The lower the score the better the patient is doing. When the questionnaire is scored, it is possible to review all of the scores for this patient in a longitudinal fashion which will give some indication of the progress the patient is or is not making.

Living With Heart Failure Que	stic	nna	aire				
If you are sure an item does not apply to you or is not related to your							
If an item does apply to you then select the number rating how much it prev	ented y No		n living Little	as yo	10000	nted. / Much	Return
Print Form	0	1	2	3	4	5	
1. Causing swelling in your ankles, legs, etc.?	0	0	0	0	0	C	
2. Making your working around the house or yard more difficult?	0	0	0	0	0	C	
3. Making your relating to or doing things with your friends or family difficult?	C	0	0	0	0	0	
4. Making you sit or lie down to rest during the day?	0	0	0	0	0	0	
5. Making you tired, fatigued or low on energy?	0	C	0	0	0	C	
6. Making your working to earn a living difficult?	0	0	0	0	0	C	
7. Making your walking about or climbing up stairs difficult?	C	0	0	0	0	C	
8. Making you short of breath?	0	0	0	0	0	ò	
9. Making your sleeping well at night difficult?	0	0	0	0	0	C	
10. Making you eat less of the foods you like?	0	0	C.	0	0	õ	
11. Making your going places away from home difficult?	0	0	0	0	0	ò	
12. Making your sexual activities difficult?	0	0	0	0	0	ò	
13. Making your recreational pasttimes, sports, or hobbies difficult?	0	0	0	0	0	0	
14. Making it difficult for you to concentrate and remember things?	0	0	C	0	0	C	
15. Giving you side effects from medications?	0	0	C	0	0	C	
16. Making you worry?	C	0	0	0	0	C	
17. Making you feel depressed?	0	0	0	0	0	C	
18. Costing you money for medical care?	0	0	0	0	0	C	
19. Making you feel a loss of self-control of your life?	0	0	C	C	0	C .	
20. Making you stay in the hospital?	0	0	0	0	0	0	
21. Making you feel you are a burden to your family or friends?	0	0	C	C	0	0	
Previous Questionnaire Results							
Encounter Date: Time Total Points							
						er your score	
				une	Dette	er off you are.	
						1	
							Þ

## Flow sheet Template

The name of this template is, "**Prospective Data Collection Flow sheet**." The data which is automatically collected on each patient when the CHF templates are given is in accordance with the Physician Consortium for Performance Improve Data Set on CHF. The elements of this data set are:

- Assessment of clinical Symptoms of Volume Overload (Excess)
- Level of Activity
- Assessment of clinical Sign of Volume overload (excess)
- Patient Education
- Beta-Blocker Therapy
- Ace Inhibitor Therapy
- Warfarin Therapy

Chronic Hx paroxysmal Atrial Fib

Once the evaluation of a patient with CHF is complete, the provider can review this template to see if all of the elements of a quality evaluation of a patient with CHF have been met.

UT II	F Manag	gement	1	Patient Rober	t Test Jr		Home
als of Therapy	Differentiati		Causes	Sex	M Age [	39	Nursing
Diagno	sing	Classification					Histories
al Signs			Most Recent L	abs Check for Nev	v Labs		Health
ight 7	2.00 inches		Sodium	11	Cholesterol 1	the second secon	Questionnaires
	00 pounds		Potassium		Triglycerides 1	75 06/06/2007	System Review
L dγFat 2	2 %		Chloride CO2				Physical Exam
R	cal/day		Glucose	11	Chol/HDL		Radiology
-	00 inches		BUN	11	Trig/HDL		Procedures
-	00 inches		Creatinine Calcium		UA Protein T3		Treatment Guide
od Pressure			Troponin		T4		Treatment Plan
	mmHg		СРК	11	17	11	CHF Questionnaire
se   st Echo	11		Digoxin	11	T-Uptake		Flowsheet
,	00	Help	PT	- 11	TSH proBNP		
	Systolic	Help	Fibrinogen	11	Sed Rate		_
	Class II	Help	PAI-1	11	D-Dimer	11	
mingham 10-Yr R	isk	%					Patient Info
tality Risk				Medical History	Labs Over T	ime	Provider Info
<u>bal Cardio Risk</u>	1.4	l					CHF Primer
							Treatment
							Diagnosing Adults

Prospective Data Collection Flowsheet							
	No Yes						
Assessment of Clinical Symptoms of Volume Overload (Excess)	□     □     Dyspnea     Return       □     □     Fatique       □     □     Orthopnea       ☑     Standardized scale or assessment tool used     Questionnaire Score						
Level of Activity	Standardized scale or assessment tool used						
Assessment of Clinical Signs of Volume Overload (Excess)	Peripheral Edema     Rales     Liver Enlarged (Hepatomegaly)     Ascites     Jugular Venous Pulse - Normal     Jugular Venous Pulse - Distended						
Patient Education	Patient Education Given						
Beta-Blocker Therapy	Not Indicated Prescribed Not Prescribed (Medical Reasons) Not Prescribed (Patient Reasons) Patient refuses a B-blocker						
Ace Inhibitor Therapy	Not Indicated Prescribed Not Prescribed Not Prescribed (Patient Reasons) Patient Receiving Angiotensin Receptor Blocker Patient refuses an ACE Patient refuses an ARB						
Warfarin Therapy Chronic Hx Paroxysmal Atrial Fib 「	✓ Not Indicated         □ Prescribed         □ Not Prescribed (Medical Reasons)         □ Not Prescribed (Patient Reasons)	-					

**Rails** – automatic documentation from respiratory physical examination template. The documentation of the presences or the absence of rails is one of the quality indicators established by the Physicians Consortium for performance improvements.

The final step is to give the patient a copy of the CHF follow-up note.